215 related articles for article (PubMed ID: 32440819)
1. Elevated vitreous αB-crystallin in patients with rhegmatogenous retinal detachment and association with proliferative vitreoretinopathy and retinal detachment area.
Yun J; Min JK
Int Ophthalmol; 2020 Oct; 40(10):2461-2467. PubMed ID: 32440819
[TBL] [Abstract][Full Text] [Related]
2. Level of vitreous alpha-B crystallin in eyes with rhegmatogenous retinal detachment.
Baba T; Oshitari T; Yamamoto S
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1251-4. PubMed ID: 25311653
[TBL] [Abstract][Full Text] [Related]
3. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
4. Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.
Symeonidis C; Androudi S; Georgalas I; Tzamalis A; Chalvatzis N; Rotsos T; Souliou E; Diza E; Dimitrakos SA
Clin Exp Immunol; 2015 Aug; 181(2):338-42. PubMed ID: 25766782
[TBL] [Abstract][Full Text] [Related]
5. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
6. Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study.
Begum G; O'Neill J; Chaudhary R; Blachford K; Snead DRJ; Berry M; Scott RAH; Logan A; Blanch RJ
Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):4929-4936. PubMed ID: 30347087
[TBL] [Abstract][Full Text] [Related]
7. Levels of Anti-Retinal Antibodies in Retinal Detachment and Proliferative Vitreoretinopathy.
Ichinohasama R; Nishiguchi KM; Fujita K; Aizawa N; Inoue T; Sasaki E; Kunikata H; Nakazawa T
Curr Eye Res; 2018 Jun; 43(6):804-809. PubMed ID: 29547015
[TBL] [Abstract][Full Text] [Related]
8. Vitreous levels of intercellular adhesion molecule 1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy.
Limb GA; Chignell AH
Br J Ophthalmol; 1999 Aug; 83(8):953-6. PubMed ID: 10413701
[TBL] [Abstract][Full Text] [Related]
9. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
10. Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade.
Symeonidis C; Papakonstantinou E; Androudi S; Georgalas I; Rotsos T; Karakiulakis G; Diza E; Dimitrakos SA
Cytokine; 2014 Jun; 67(2):71-6. PubMed ID: 24725542
[TBL] [Abstract][Full Text] [Related]
11. Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment.
Palomares-Ordóñez JL; Sánchez-Ramos JA; Ramírez-Estudillo JA; Robles-Contreras A
Arch Soc Esp Oftalmol (Engl Ed); 2019 Jan; 94(1):12-17. PubMed ID: 30309666
[TBL] [Abstract][Full Text] [Related]
12. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Chemokine CXCL-1 and Interleukin-6 Concentrations in the Subretinal Fluid and Vitreous in Rhegmatogenous Retinal Detachment.
Symeonidis C; Rotsos T; Matsou A; Dermenoudi M; Georgalas I; Tsinopoulos I; Makri O; Souliou E; Dimitrakos SA
Ocul Immunol Inflamm; 2021 Feb; 29(2):355-361. PubMed ID: 31661651
[No Abstract] [Full Text] [Related]
14. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
15. Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy.
Ni Y; Qin Y; Huang Z; Liu F; Zhang S; Zhang Z
Adv Ther; 2020 May; 37(5):2550-2559. PubMed ID: 32274748
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of vitreoschisis-induced vitreous cortex remnants over the peripheral retinal surface in eyes undergoing vitrectomy for primary rhegmatogenous retinal detachment.
van Overdam KA; van Etten PG; Accou GPBM; Wubbels RJ; van Meurs JC; Verhoekx JSN
Acta Ophthalmol; 2024 Feb; 102(1):99-106. PubMed ID: 37133363
[TBL] [Abstract][Full Text] [Related]
17. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
18. Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Kaarniranta K; Resch MD
BMC Ophthalmol; 2020 Dec; 20(1):491. PubMed ID: 33371882
[TBL] [Abstract][Full Text] [Related]
19. Vitreous M2 Macrophage-Derived Microparticles Promote RPE Cell Proliferation and Migration in Traumatic Proliferative Vitreoretinopathy.
Song Y; Liao M; Zhao X; Han H; Dong X; Wang X; Du M; Yan H
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):26. PubMed ID: 34554178
[TBL] [Abstract][Full Text] [Related]
20. Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.
Kenarova B; Voinov L; Apostolov C; Vladimirova R; Misheva A
Eur J Ophthalmol; 1997; 7(1):64-7. PubMed ID: 9101198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
